Abstract
Despite strong biological rationale for the use of type-I IFNs for the treatment of acute myeloid leukemia (AML), their usage is limited to few hematologic malignancies. Here, we propose that innate immune sensing machinery, particularly the stimulator of IFN genes pathway, may be exploited to deliver antileukemic effects in AML.
Footnotes
Mol Cancer Res 2021;XX:XX–XX
- Received October 6, 2020.
- Revision received November 20, 2020.
- Accepted January 21, 2021.
- Published first January 26, 2021.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on February 16, 2021
doi: 10.1158/1541-7786.MCR-20-0871
Old Dog, New Trick: Type I IFN–based Treatment for Acute Myeloid Leukemia
Jump to section
Advertisement